

DAFTAR PUSTAKA

- Alexander, B.M., & Cloughesy, T.F. (2017). Adult glioblastoma. *J. Clin. Oncol.*
- An, Z., Aksoy, O., Zheng, T., Fan, Q.W., & Weiss, W.A. (2018). Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. *Oncogene.*
- Antonelli, M., & Poliani, P.L. (2022). Adult type diffuse gliomas in the new 2021 WHO Classification. *Pathologica.*
- Badve, C., & Kanekar, S. (2021). Radiogenomics of Gliomas. *Radiol. Clin. North Am.*
- Bai, J., Varghese, J., & Jain, R. (2020). Adult glioma WHO classification update, genomics, and imaging: What the radiologists need to know. *Top. Magn. Reson. Imaging.*
- Barnholtz-Sloan, J.S., Ostrom, Q.T., & Cote, D. (2018). Epidemiology of Brain Tumors. *Neurol. Clin.*
- Bell, R.J.A., Rube, H.T., Xavier-Magalhães, A., Costa, B.M., Mancini, A., Song, J.S., *et al.* (2016). Understanding TERT promoter mutations: A common path to immortality. *Mol. Cancer Res.*
- Bihan, D. Le (2013). Apparent diffusion coefficient and beyond: what diffusion MR imaging can tell us about tissue structure. *Radiology* 268 : 318–322.
- Byun, Y.H., & Park, C.-K. (2022). Classification and Diagnosis of Adult Glioma: A Scoping Review. *Brain & Neurorehabilitation* 15.
- Claus, E.B., Cannataro, V.L., Gaffney, S.G., & Townsend, J.P. (2022). Environmental and sex-specific molecular signatures of glioma causation. *Neuro. Oncol.* 24.
- Corell, A., Ferreyra Vega, S., Hoefling, N., Carstam, L., Smits, A., Olsson Bontell, T., *et al.* (2020). The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: A population-based study. *BMC Cancer* 20.
- Dahlan, M. (2016). Besar Sampel dalam Penelitian Kedokteran dan Kesehatan, Sagung Seto.
- Dahlrot, R.H., Bangsø, J.A., Petersen, J.K., Rosager, A.M., Sørensen, M.D., Reifenberger, G., *et al.* (2021). Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. *Sci. Rep.* 11.
- DeSisto, J., Lucas, J.T., Xu, K., Donson, A., Lin, T., Sanford, B., *et al.* (2021). Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. *Nat. Commun.* 12.

- DeWeerdt, S. (2018). The genomics of brain cancer. *Nature*.
- Drake-Pérez, M., Boto, J., Fitsiori, A., Lovblad, K., & Vargas, M.I. (2018). Clinical applications of diffusion weighted imaging in neuroradiology. *Insights Imaging* 9 : 535.
- Du, N., Shu, W., Li, K., Deng, Y., Xu, X., Ye, Y., *et al.* (2023). An initial study on the predictive value using multiple MRI characteristics for Ki-67 labeling index in glioma. *J. Transl. Med.* 21.
- Fangusaro, J. (2012). Pediatric high grade glioma: A review and update on tumor clinical characteristics and biology. *Front. Oncol.*
- Gühr, G.A., Horvath-Rizea, D., Hekeler, E., Ganslandt, O., Henkes, H., Hoffmann, K.T., *et al.* (2020). Histogram Analysis of Diffusion Weighted Imaging in Low-Grade Gliomas: in vivo Characterization of Tumor Architecture and Corresponding Neuropathology. *Front. Oncol.* 10.
- Girardi, F., Matz, M., Stiller, C., You, H., Gragera, R.M., Valkov, M.Y., *et al.* (2023). Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3). *Neuro. Oncol.* 25.
- Grochans, S., Cybulska, A.M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., *et al.* (2022). Epidemiology of Glioblastoma Multiforme–Literature Review. *Cancers (Basel)*.
- Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., *et al.* (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J. Exp. Med.* 207.
- Hauptmann, M., Byrnes, G., Cardis, E., Bernier, M.O., Blettner, M., Dabin, J., *et al.* (2023). Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study. *Lancet Oncol.* 24.
- Hu, Y., & Zhang, K. (2024). Noninvasive assessment of Ki-67 labeling index in glioma patients based on multi-parameters derived from advanced MR imaging. *Front. Oncol.* 14 : 1–11.
- Iorgulescu, J.B., Sun, C., Neff, C., Cioffi, G., Gutierrez, C., Kruchko, C., *et al.* (2022). Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. *Neuro. Oncol.* 24.
- Irelli, A., Sirufo, M.M., D’Ugo, C., Ginaldi, L., & De Martinis, M. (2020). Sex and gender influences on cancer immunotherapy response. *Biomedicines*.
- Jenkins, R.B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R.M., Law, M., *et al.* (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer*

Res. 66.

- July, J., Patricia, D., Gunawan, P.Y., Setiajaya, H., Ginting, T.E., Putra, T.P., *et al.* (2020). Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. *Pan Afr. Med. J.* 36.
- Kim, M., Jung, S.Y., Park, J.E., Jo, Y., Park, S.Y., Nam, S.J., *et al.* (2020). Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. *Eur. Radiol.* 30.
- Kim, M., Ladomersky, E., Mozny, A., Kocherginsky, M., O'shea, K., Reinstein, Z.Z., *et al.* (2021). Glioblastoma as an age-related neurological disorder in adults. *Neuro-Oncology Adv.* 3.
- Komori, T. (2022). The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles. *Brain Tumor Pathol.*
- Leece, R., Xu, J., Ostrom, Q.T., Chen, Y., Kruchko, C., & Barnholtz-Sloan, J.S. (2017). Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. *Neuro. Oncol.* 19.
- Lin, E., Raine, T., Alonso, A., & Michaud, D. (2007). Atopy and risk of brain tumors: A meta-analysis. *J. Natl. Cancer Inst.* 99.
- Liu, X.Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.A., Fontebasso, A.M., *et al.* (2012). Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta Neuropathol.* 124.
- Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., *et al.* (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. *Neuro. Oncol.* 23.
- Mansouri, A., Hachem, L.D., Mansouri, S., Nassiri, F., Laperriere, N.J., Xia, D., *et al.* (2019). MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges. *Neuro. Oncol.* 21.
- McKinnon, C., Nandhabalan, M., Murray, S.A., & Plaha, P. (2021). Glioblastoma: Clinical presentation, diagnosis, and management. *BMJ.*
- Momeni, F., Abedi-Firouzjah, R., Farshidfar, Z., Taleinezhad, N., Ansari, L., Razmkon, A., *et al.* (2021). Differentiating between low-and high-grade glioma tumors measuring apparent diffusion coefficient values in various regions of the brain. *Oman Med. J.* 36.
- Muir, M., Gopakumar, S., Traylor, J., Lee, S., & Rao, G. (2020). Glioblastoma multiforme: novel therapeutic targets. *Expert Opin. Ther. Targets.*
- Nielsen, L.A.G., Bangsø, J.A., Lindahl, K.H., Dahlrot, R.H., Hjelmberg, J.V.B.,

- Hansen, S., *et al.* (2018). Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. *Diagn. Pathol.* 13.
- Oncu, S., Serifoglu, İ., Arslan, F.Z., Karagulle, M., Simsek, S., Kaya, G.G., *et al.* (2022). Correlation of morphologic findings and apparent diffusion coefficient values with Ki-67 proliferation index in patients with glioblastoma. *Eur. Res. J.* 8 : 790–799.
- Ostrom, Q.T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J.S. (2021). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro. Oncol.* 23.
- Ostrom, Q.T., Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C., *et al.* (2023). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. *Neuro. Oncol.*
- Pacifico, A., & Leone, G. (2007). Role of p53 and CDKN2A inactivation in human squamous cell carcinomas. *J. Biomed. Biotechnol.*
- Peeters, M.C.M., Dirven, L., Koekkoek, J.A.F., Gortmaker, E.G., Fritz, L., Vos, M.J., *et al.* (2020). Prediagnostic symptoms and signs of adult glioma: the patients' view. *J. Neurooncol.* 146.
- Perez, A., & Huse, J.T. (2021). The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021. *Curr. Neurol. Neurosci. Rep.*
- Posti, J.P., Bori, M., Kauko, T., Sankinen, M., Nordberg, J., Rahi, M., *et al.* (2015). Presenting symptoms of glioma in adults. *Acta Neurol. Scand.* 131.
- Pradhan, R., Kundu, A., & Kundu, C.N. (2024). The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth. *Crit. Rev. Oncol. Hematol.*
- Qi, S., Yu, L., Li, H., Ou, Y., Qiu, X., Ding, Y., *et al.* (2014). Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. *Oncol. Lett.* 7.
- Rasmussen, B.K., Hansen, S., Laursen, R.J., Kosteljanetz, M., Schultz, H., Nørgård, B.M., *et al.* (2017). Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry. *J. Neurooncol.* 135.
- Rojas, A., Lindner, C., Schneider, I., González, I., Araya, H., Morales, E., *et al.* (2021). Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer. *World J. Gastrointest. Oncol.* 13.
- Schmidt-Hansen, M., Berendse, S., & Hamilton, W. (2015). Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: A systematic review. *Fam. Pract.*
- Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D.E., Sahm, F., *et al.*

- (2018). Novel, improved grading system(S) for IDH-mutant astrocytic gliomas. *Acta Neuropathol.* 136.
- Śledzińska, P., Bebyn, M.G., Furtak, J., Kowalewski, J., & Lewandowska, M.A. (2021). Prognostic and predictive biomarkers in gliomas. *Int. J. Mol. Sci.*
- Smits, M. (2021). Update on neuroimaging in brain tumours. *Curr. Opin. Neurol.*
- Smits, M., & Van Den Bent, M.J. (2017). Imaging correlates of adult glioma genotypes. *Radiology.*
- Stichel, D., Ebrahimi, A., Reuss, D., Schrimpf, D., Ono, T., Shirahata, M., *et al.* (2018). Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathol.* 136.
- Sun, C., Xiao, L., Zhao, Y., Shi, J., Yuan, Y., Gu, Y., *et al.* (2020). Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma. *Transl. Oncol.* 13.
- Sun, G., Wang, X., Shi, L., Yue, X., Fu, L., Chen, C., *et al.* (2013). Association between polymorphisms in interleukin-4R α and interleukin-13 and glioma risk: A meta-analysis. *Cancer Epidemiol.* 37.
- Takaya, Y., Chen, H., TEN, H., Hoya, K., Jiang, C., Oyama, K., *et al.* (2021). Evaluation of the malignant potential of gliomas using diffusion-weighted and gadolinium-enhanced magnetic resonance imaging. *Brain Sci. Adv.* 7 : 248–256.
- Taylor, A.J., Little, M.P., Winter, D.L., Sugden, E., Ellison, D.W., Stiller, C.A., *et al.* (2010). Population-based risks of CNS tumors in survivors of childhood cancer: The British childhood cancer survivor study. *J. Clin. Oncol.* 28.
- Taylor, S.R., Ewings, S.M., Jaynes, E., Tilley, C., Ellis, S.G., Armstrong, T., *et al.* (2016). The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: A systematic review and meta-analysis. *J. Clin. Pathol.* 69.
- Thon, N., Kreth, S., & Kreth, F.W. (2013). Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. *Onco. Targets. Ther.*
- Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J.C., Minniti, G., *et al.* (2021). EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat. Rev. Clin. Oncol.* 18.
- Wesseling, P., van den Bent, M., & Perry, A. (2015). Oligodendroglioma: pathology, molecular mechanisms and markers. *Acta Neuropathol.*
- Yao, R., Cheng, A., Liu, M., Zhang, Z., Jin, B., & Yu, H. (2021). The Diagnostic Value of Apparent Diffusion Coefficient and Proton Magnetic Resonance Spectroscopy in the Grading of Pediatric Gliomas. *J. Comput. Assist. Tomogr.* 45.



UNIVERSITAS
GADJAH MADA

Korelasi Nilai Apparent Diffusion Coefficient Pada Magnetic Resonance Imaging dengan Index Proliferasi Ki-67 pada Pasien Glioma Difus Tipe Dewasa
Sofiansyah Yosef, Prof. dr. Arif Faisal, Sp. Rad (K) N-KL, DHSM.; dr. Sri Retna Dwidanarti, Sp. Rad (K)-ONK
Universitas Gadjah Mada, 2025 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Yao, R., Cheng, A., Zhang, Z., Jin, B., & Yu, H. (2023). Correlation Between Apparent Diffusion Coefficient and the Ki-67 Proliferation Index in Grading Pediatric Glioma. *J. Comput. Assist. Tomogr.* 47.